Skip to main content

Mark Tyndall

Photo of Mark Tyndall
Mark Tyndall is the Lead of Research and Evaluation for the PHSA Opioid Overdose Response Team and a Professor with UBC's School of Population and Public Health.


Dr. Tyndall’s research focus is public health and disadvantaged populations. His current research interests include addiction, poverty, homelessness, drug overdose and drug policy. He also studies harm reduction, including supervised injection sites, regulated drug distribution and nicotine harm reduction (e-cigarettes and vaping) and has an interest in community-based research conducted with the involvement of people with lived experience. 


Dr. Mark Tyndall’s primary focus is his public health work on the overdose crisis response. Dr. Tyndall is working on a Heath Canada-funded pilot project to provide a safer supply of drugs to people who are dependent on the toxic street drug supply. Dr. Tyndall joined BCCDC in 2014 and previously served as the Executive Medical Director. He is also a Professor at the UBC School of Population and Public Health. Prior to coming to Vancouver, he was the Chief of the Division of Infectious Diseases at the University of Ottawa and a Senior Scientist at the Ottawa Hospital Research Institute. His career awards include the Michael Smith Foundation for Health Research Senior Scholar Award and the Ontario HIV Treatment Network Applied Research Chair. 

Dr. Tyndall, MD, ScD, FRCPC, received his medical degree and internal medicine training at McMaster University and his infectious diseases fellowship training at the University of Manitoba. He received a doctoral degree in epidemiology from Harvard University with a focus on health and human rights. He has conducted international research and consultation in a number of countries and resided in Kenya for four years as part of the WHO collaborative research group on HIV. From 1999 to 2010 he was the Program Director for Epidemiology at the BC Centre for Excellence in HIV/AIDS and was co-lead investigator on the evaluation of Insite, North America’s first supervised injection site. He has conducted numerous community-based research projects in Vancouver and Ottawa, including epidemiologic studies of HIV and Hepatitis C transmission, antiretroviral access among injection drug users, and health-care utilization among marginalized populations. Dr. Tyndall is a strong advocate and leader for public health in Canada and has fostered a number of community-based collaborations that have led to health policy changes. He was the co-founder of Physicians for Refugee Health and has advocated for enhanced harm-reduction interventions and the de-criminalization of drug use.


SOURCE: Mark Tyndall ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Centre for Disease Control. All Rights Reserved.

    Copyright © 2019 Provincial Health Services Authority.